-
Je něco špatně v tomto záznamu ?
The markers of the organic acidemias and their ratios in healthy neonates in Serbian population
A. Beletić, A. Tijanić, P. Chrastina, T. Nikolić, A. Stefanović, S. Stanković
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
PubMed
35254746
DOI
10.1515/dmpt-2021-0218
Knihovny.cz E-zdroje
- MeSH
- biologické markery MeSH
- glutaryl-CoA-dehydrogenasa nedostatek MeSH
- isovaleryl-CoA-dehydrogenasa MeSH
- lidé MeSH
- metabolické nemoci mozku MeSH
- novorozenec MeSH
- propionová acidemie * diagnóza MeSH
- vrozené poruchy metabolismu aminokyselin MeSH
- Check Tag
- lidé MeSH
- novorozenec MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Srbsko MeSH
OBJECTIVES: The newborn screening (NBS) program in the Republic of Serbia has several decades of tradition, but it has not included any organic acidemias (OA). Therefore, this study aimed to establish the cut-offs of the corresponding NBS markers in the population of healthy newborns. METHODS: In dried blood samples (DBS) collected from 1,771 healthy newborns, we analyzed levels of propionylcarnitine (C3), isovalerylcarnitine (C5), and glutarylcarnitine (C5DC) using tandem mass spectrometry. Further we calculated the following ratios: C3/acetylcarnitine (C3/C2), C3/palmitoylcarnitine (C3/C16), C5/ free carnitine (C0), C5/C2, C5/C3, C5DC/octanoylcarnitine (C8), and C5DC/C0. RESULTS: The cut-offs for methylmalonic acidemia (MMA) or propionic acidemia (PA) were C3>5.73 μmol/L, C3/C2>0.23, and C3/C16>2.36. Based on the study findings, the screening results indicative for isovaleric acidemia (IVA) would include C5>0.372 μmol/L, C5/C0>0.020, C5/C2>0.019, and C5/C3>0.31. Finally, C5DC>0.303 μmol/L, C5DC/C8>7.1, and C5DC/C0>0.019 would justify further testing for glutaric acidemia type I (GA1). The cut-offs were satisfactorily validated via the comparison with worldwide estimates and data for several Caucasian populations. CONCLUSIONS: The levels of the OA biomarkers in the Serbian population of healthy newborns have a distribution pattern similar to the other world populations. Therefore, the proposed cut-offs represent a reliable starting point for the future development of the OA NBS.
Center for Medical Biochemistry University Clinical Center of Serbia Belgrade Serbia
Clinic for Gynecology and Obstetrics University Clinical Centre of Serbia Belgrade Serbia
Faculty of Medical Sciences University of Kragujevac Kragujevac Serbia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22025468
- 003
- CZ-PrNML
- 005
- 20221031100349.0
- 007
- ta
- 008
- 221017s2022 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1515/dmpt-2021-0218 $2 doi
- 035 __
- $a (PubMed)35254746
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Beletić, Anđelo $u Center for Medical Biochemistry, University Clinical Center of Serbia, Belgrade, Serbia $1 https://orcid.org/0000000189759600
- 245 14
- $a The markers of the organic acidemias and their ratios in healthy neonates in Serbian population / $c A. Beletić, A. Tijanić, P. Chrastina, T. Nikolić, A. Stefanović, S. Stanković
- 520 9_
- $a OBJECTIVES: The newborn screening (NBS) program in the Republic of Serbia has several decades of tradition, but it has not included any organic acidemias (OA). Therefore, this study aimed to establish the cut-offs of the corresponding NBS markers in the population of healthy newborns. METHODS: In dried blood samples (DBS) collected from 1,771 healthy newborns, we analyzed levels of propionylcarnitine (C3), isovalerylcarnitine (C5), and glutarylcarnitine (C5DC) using tandem mass spectrometry. Further we calculated the following ratios: C3/acetylcarnitine (C3/C2), C3/palmitoylcarnitine (C3/C16), C5/ free carnitine (C0), C5/C2, C5/C3, C5DC/octanoylcarnitine (C8), and C5DC/C0. RESULTS: The cut-offs for methylmalonic acidemia (MMA) or propionic acidemia (PA) were C3>5.73 μmol/L, C3/C2>0.23, and C3/C16>2.36. Based on the study findings, the screening results indicative for isovaleric acidemia (IVA) would include C5>0.372 μmol/L, C5/C0>0.020, C5/C2>0.019, and C5/C3>0.31. Finally, C5DC>0.303 μmol/L, C5DC/C8>7.1, and C5DC/C0>0.019 would justify further testing for glutaric acidemia type I (GA1). The cut-offs were satisfactorily validated via the comparison with worldwide estimates and data for several Caucasian populations. CONCLUSIONS: The levels of the OA biomarkers in the Serbian population of healthy newborns have a distribution pattern similar to the other world populations. Therefore, the proposed cut-offs represent a reliable starting point for the future development of the OA NBS.
- 650 _2
- $a vrozené poruchy metabolismu aminokyselin $7 D000592
- 650 _2
- $a biologické markery $7 D015415
- 650 _2
- $a metabolické nemoci mozku $7 D001928
- 650 _2
- $a glutaryl-CoA-dehydrogenasa $x nedostatek $7 D050770
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a novorozenec $7 D007231
- 650 _2
- $a isovaleryl-CoA-dehydrogenasa $7 D050769
- 650 12
- $a propionová acidemie $x diagnóza $7 D056693
- 651 _2
- $a Srbsko $7 D055771
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Tijanić, Aleksandra $u Center for Medical Biochemistry, University Clinical Center of Serbia, Belgrade, Serbia
- 700 1_
- $a Chrastina, Petr $u Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Nikolić, Tatjana $u Clinic for Gynecology and Obstetrics, University Clinical Centre of Serbia, Belgrade, Serbia
- 700 1_
- $a Stefanović, Aleksandar $u Clinic for Gynecology and Obstetrics, University Clinical Centre of Serbia, Belgrade, Serbia $u School of Medicine, University of Belgrade, Belgrade, Serbia
- 700 1_
- $a Stanković, Sanja $u Center for Medical Biochemistry, University Clinical Center of Serbia, Belgrade, Serbia $u Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
- 773 0_
- $w MED00197248 $t Drug metabolism and personalized therapy $x 2363-8915 $g Roč. 37, č. 3 (2022), s. 271-275
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35254746 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031100347 $b ABA008
- 999 __
- $a ok $b bmc $g 1854935 $s 1176758
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 37 $c 3 $d 271-275 $e 20220307 $i 2363-8915 $m Drug metabolism and personalized therapy $n Drug Metab Pers Ther $x MED00197248
- LZP __
- $a Pubmed-20221017